Sangamo Therapeutics, Inc.
7000 Marina Blvd
Brisbane
CA
94005
United States
Tel: (510) 970-6000
Website: https://www.sangamo.com/
Email: hr@sangamo.com
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. At Sangamo, we are passionate in developing genomic medicines to transform the lives of patients with serious diseases. We transform lives by building a robust, sustainable, differentiated, innovative, and high value genomic medicine pipeline that addresses patients with life-limiting conditions. Sangamo takes pride in being the first to edit endogenous human genes, first to treat patients with gene edited T cells, and first to treat patients with in vivo genome editing. Our top priority is to meet the needs of patients with commitment and compassion. Along with our commitment to science and to our patients, we also endeavor to create an inclusive environment that promotes and values diversity. Sangamo is a company where individuals can flourish, grow and develop their expertise.
We are seeking top talent to join our mission. Let’s build a better future together.
Stock Symbol: SGMO
590 articles with Sangamo Therapeutics, Inc.
-
Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer
9/30/2019
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer.
-
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences in September 2019
8/30/2019
Sangamo Therapeutics, Inc. announced that management will present at the following investor conferences in September
-
Sangamo Therapeutics Reports Second Quarter 2019 Financial Results
8/7/2019
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported second quarter 2019 financial results and recent business highlights.
-
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - Aug. 6, 2019
8/6/2019
Sangamo Therapeutics, Inc., a genomic medicine company, announced that CEO Sandy Macrae will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City.
-
Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel
7/31/2019
Sangamo Therapeutics, Inc., a genomic medicine company, announced the appointment of Gary H. Loeb as Executive Vice President and General Counsel, effective immediately.
-
Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast
7/31/2019
Sangamo Therapeutics, Inc., a genomic medicine company, announced that the Company will release its second quarter 2019 financial results after the market closes on Wednesday, August 7, 2019.
-
Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases
7/29/2019
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the publication in Nature Biotechnology of a manuscript by Jeffrey Miller, Ph.D., and colleagues at Sangamo, describing two new strategies for optimizing the specificity of genome editing using zinc finger nucleases (ZFNs)
-
Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels
7/6/2019
Sangamo Therapeutics, Inc. and Pfizer, Inc. announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A.
-
Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger Proteins in Preclinical Models of Huntington’s Disease
7/1/2019
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the publication of a manuscript describing the activity of allele-selective zinc finger protein transcription-factors (ZFP-TFs) in preclinical models of Huntington’s disease (HD).
-
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019
6/21/2019
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced the upcoming presentation of data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A
-
Andrew Douthwaite, chief technology officer for Colorado-based VirtualArmour, a cybersecurity company, told BioSpace that biotech and pharma companies are desirable targets for hackers and cyber thieves due to the value of the intellectual property.
-
Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences
5/15/2019
Hemophilia A SB-525 gene therapy clinical data accepted for oral presentation at ISTH
-
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference
5/10/2019
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that Sangamo will participate in the Bank of America Merrill Lynch 2019 Health Care Conference being held next week in Las Vegas
-
Sangamo Therapeutics Reports First Quarter 2019 Financial Results
5/8/2019
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported first quarter 2019 financial results and recent business highlights.
-
Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast
5/1/2019
Sangamo Therapeutics, Inc. announced that the Company will release its first quarter 2019 financial results after the market closes on Wednesday, May 8, 2019.
-
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - April 8, 2019
4/8/2019
Sangamo Therapeutics, Inc. announced the completion of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a price to the public of $11.50 per share, including 1,650,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares.
-
Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock
4/4/2019
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $11.50 per share.
-
Sangamo Therapeutics Announces Proposed Public Offering of Common Stock
4/3/2019
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that it has commenced an underwritten public offering of shares of its common stock.
-
The California-based company also shared positive early data from a beta thalassemia study and announced plans to increase AAV manufacturing.
-
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
4/2/2019
Conference call and webcast scheduled for 8:00 a.m. Eastern Time